文献速递免疫规划

非洲婴幼儿中与常规扩大免疫规划疫苗同时接种的A群脑膜炎球菌结合疫苗的免疫原性与安全性

Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.
PubMed 文献 · Vaccine · 2025-09-17

研究在加纳和马里开展两项随机对照试验,评估不同剂量PsA-TT与扩大免疫规划疫苗同时接种的免疫原性与安全性。结果显示5 μg和2.5 μg对10 μg的非劣效性成立,接种后28天MenA rSBA血清转换率≥93%,与多数EPI抗原非劣效,不良事件组间相似,为WHO推荐5 μg单剂纳入EPI奠定基础。

要点

  • 5 μg和2.5 μg PsA-TT对10 μg的非劣效性在Study A中成立,每剂后28天MenA rSBA血清转换率≥93%。
  • Study B中5 μg对10 μg在9-12和15-18月龄两剂及9-12月龄单剂方案下血清转换率≥97%,非劣效性成立。
  • 两项研究中与多数EPI抗原非劣效,不良事件和严重不良事件在各疫苗组间相似。

核心结论

  • 两项试验结果表明PsA-TT与EPI疫苗同时接种时安全且有免疫原性,为WHO推荐5 μg PsA-TT作为单剂在9-18月龄纳入EPI铺平了道路。

研究设计与样本

  • Study A为2008至2012年在加纳开展的2期随机对照试验,评估10 μg、5 μg或2.5 μg MenA多糖的PsA-TT剂型在14-18周、9-12月和12-18月龄与EPI疫苗同时接种一剂或两剂的安全性和免疫原性。
  • Study B为2012至2013年在马里开展的3期随机对照试验,评估10 μg和5 μg剂型在9-12和15-18月龄与EPI疫苗同时接种一剂或两剂。
  • 免疫原性采用兔补体血清杀菌抗体试验(rSBA)评估。

主要发现

  • Study A中5 μg和2.5 μg PsA-TT对10 μg的非劣效性成立,每剂后28天MenA rSBA血清转换率≥93%。
  • Study B中5 μg对10 μg在9-12和15-18月龄两剂及9-12月龄单剂方案下28天MenA rSBA血清转换率≥97%,非劣效性成立。
  • 两项研究成对比较中,对多数EPI抗原的非劣效性成立。
  • 两项研究中接种后报告的不良事件和严重不良事件在各疫苗组间相似。

关键数值与推荐

  • Study A:5 μg和2.5 μg PsA-TT对10 μg的非劣效性成立,每剂后28天MenA rSBA血清转换率≥93%。
  • Study B:5 μg对10 μg在9-12和15-18月龄两剂及9-12月龄单剂方案下28天MenA rSBA血清转换率≥97%,非劣效性成立。
  • 两项研究中对多数EPI抗原的非劣效性成立。

临床怎么用

  • 原文结论指出结果支持WHO推荐将5 μg PsA-TT作为单剂在9-18月龄纳入EPI。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2010, a Meningococcal group A (MenA) conjugate vaccine (PsA-TT) was WHO prequalified and introduced in preventive campaigns in 1-29 year-olds across the African Meningitis Belt. An extension of the indication to infants and toddlers in the Expanded Programme on Immunization (EPI) was pursued for the protection of new birth cohorts. Between 2008 and 2012, a Phase 2 randomized controlled trial was conducted in Ghana to assess the safety and immunogenicity of different PsA-TT formulations (10 μg, 5 μg or 2.5 μg of MenA polysaccharide) given as one or two doses with EPI vaccines at 14-18 weeks, 9-12 months, and 12-18 months of age (Study A). Between 2012 and 2013, a subsequent Phase 3 randomized controlled trial was conducted in Mali to assess the 10 μg and 5 μg formulations given as one or two doses with EPI vaccines at 9-12 and 15-18 months of age (Study B). Immunogenicity was assessed using a serum bactericidal antibody assay using rabbit complement (rSBA). Non-inferiority of the 5 μg and 2.5 μg PsA-TT formulations to the 10 μg formulation was demonstrated in Study A with ≥93 % seroconversion in MenA rSBA 28 days after each dose. Non-inferiority of the 5 μg to the 10 μg was demonstrated in Study B in terms of seroconversion in MenA rSBA at 28 days (≥97 %) when given as two doses at 9-12 and 15-18 months and as a single dose at 9-12 months. Non-inferiority with respect to most EPI antigens was demonstrated in pairwise comparisons across both studies. Adverse events and serious adverse events reported in either study following vaccinations were similar across vaccine groups. Results of both trials showed that the vaccine was safe and immunogenic when co-administered with the EPI, paving the way for a WHO recommendation for the 5 μg PsA-TT to be included in the EPI as a single dose at 9-18 months of age. PsA-TT-004, registered International Standard Randomized Controlled Trial Number: ISRCTN82484612; PsA-TT-007, International registration number: PACTR201110000328305.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hodgson A, Haidara FC, Sow SO, et al. Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers. Vaccine. 2025. PMID: 40966979. doi:10.1016/j.vaccine.2025.127698

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。